Professor Wilfried Posch from The University Hospital Innsbruck joins Proactive London to talk through his work with 240 patients who will take part in the Phase II double-blind placebo-controlled evaluation of the potential breakthrough in the fight against COVID-19.
The SPC-069 trial will lead to Emergency Use Authorisation applications to both the Medicines and Healthcare Products Regulatory Agency here in the UK and the European Medicines Agency.
SPC-069’s active ingredient is hypochlorous acid (HOCl), a chemical naturally produced by the human body’s white blood cells to fight infection within the body.